In response to the observed heterogeneity in CRC immunity, Galon et al. proposed the “Immunoscore”—a quantitative assessment of CD3+ and CD8+ T-cell densities in the tumor core and invasive margin—which has demonstrated superior prognostic value over traditional TNM staging (Pagès et al., 2018). This evidence concerns the gene CD8A and colorectal carcinoma.